2022.Jul.04
SUPPLEMENTARY STATEMENTS ON NEWS ARTICLE
1.Date of occurrence of the event:2022/07/04 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Name of the reporting media:2022/7/4 TechNews and InfoTimes, etc. 6.Content of the report: “OBI announces discontinuation of the Phase II Study of OBI-888…… However, the discontinuation leads to the concerns […]
This article is password protected.
To view the content, please enter your password in the field below